EN DE
Watch Biokarpet S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biokarpet S.A. (BIOKA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Biokarpet S.A. stock €2.58, price €1.47, upside +75.5%, quality 45 out of 100. Rating: strongly undervalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Cyclical GR · ISIN GRS165063009

BS Biokarpet S.A. logo Some data Nov 9, 2026

Biokarpet S.A.

BIOKA · AT
Cheap, value-trap risk

The stock costs 43% less than our calculation considers fair.

Fair value €2.58 · Strongly undervalued
Even on cautious assumptions the value is 23% above the price (€1.81).
Quality 45/100
Thin margins · 1.7% net margin (TTM)
Moderate debt
Some data
Weak Growth (revenue 3y −2.7 %/yr in EUR)
Negative free cash flow
Trails peers (3/10)
Narrow moat 30/100 · thin data
Watch Biokarpet S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€3.31 €1.31 Fair Value €2.58 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range €1.31 – €3.31 · fair‑value band €1.81 – €3.35 · the €1.47 price screens below the €2.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Biokarpet in your weekly email

Every Wednesday you see whether Biokarpet is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biokarpet S.A. engages in the metallurgy, textile, and information technology sectors in Greece, rest of European union, and internationally. It produces and trades in handmade and machine-made carpets, moquettes, blankets, flokati rugs, and other products for flooring and home decoration.

Show moreShow less

The company also offers linen and wall coverings for bed and bath; and wall to wall carpets and carpet tiles, as well as carpet cleaning and storage services.

In addition, it produces and trades in aluminum profile products and related products; provides information systems services and consulting in software and software procurement, as well as engages in wholesale of computer machines and office equipment.

Further, the company produces and distributes electricity through renewable sources. It operates a network of 50 stores, which includes 40 stores in Greece and 10 stores primarily in Romania, Bulgaria, Cyprus, Poland, and Albania, as well as offers its products online.

The company was founded in 1950 and is headquartered in Athens, Greece.

Stock analysis

Biokarpet S.A. (BIOKA) currently trades at €1.47, while our model-based Fair Value estimate is €2.58, implying the stock looks roughly 43% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €2.63 per share, and 6 of the 10 models we run sit above the €1.47 price.

Bear case: the Earnings-Based group reads lowest at €0.8300, and 4 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: €1.81 (bear) to €3.35 (bull), the price of €1.47 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Consumer Cyclical sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Biokarpet S.A. reported revenue of €213M in FY2025 versus €187M in FY2021, a compound +3.3%/yr. Reported net income was €3.2M in FY2025, compounding −6.4%/yr from FY2021.

Key figures

Market cap €35.3M Micro · P/E ratio 163.3 · P/S ratio 0.15 · EPS (TTM) €0.0090 · Net margin 1.7% · Return on equity 7.7% · Return on assets (EBIT) 5.0% (5-year average) · Operating margin 4.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Cyclical peers we cover trades at −8% fair-value upside, at 76%, BIOKA screens cheaper than that median.

Fair Value models

Bear €1.81 Fair Value €2.58 Bull €3.35
Price €1.47 · Upside +75.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.0077 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income €1.58 €1.60 €1.71 71
Growth-Adj P/E €1.81 €2.58 €3.35 67
Graham-Dodd €0.9200 €2.74 €3.63 65
All 10 models by family
Earnings-Based
Graham-Dodd €0.9200 €2.74 €3.63 65
Lynch FV €0.5800 €0.8300 €1.08 61
PEG = 1.0 €0.5800 €0.8300 €1.08 57
Multiples
P/E Multiple €2.22 €2.96 €3.71 63
P/S Multiple €1.72 €2.29 €2.86 58
P/B Multiple €6.29 €8.39 €10.48 55
EV/EBITDA n/a €1.29 €2.80 62
Asset-Based
NCAV (Graham) €1.05 €1.40 €2.10 54
Economic Profit
Residual Income €1.58 €1.60 €1.71 71
Growth Earnings
Growth-Adj P/E €1.81 €2.58 €3.35 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 36
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 21
Do the profits arrive as real cash?
Financial strength 17
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 83
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 6
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +10.1% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.2%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+21.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+21.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 2%

Watch BIOKA, get fair value alerts →

Compare Biokarpet S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Textile Manufacturing · 338 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside +75.5% · Top 25%
Profitability
Return on equity (12 months) 7.7% · Above median
Return on assets 1.6% · Below median
Net margin (12 months) 1.7% · Below median
Operating margin (12 months) 4.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 13.1% · Above median
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 1.32× · Highest 25%

Valuation Multiplesvs Textile Manufacturing median · lower = cheaper

P/E (12 months) 163.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 10
FUTURE (revenue growth)66 · sector 37
PAST (return on equity)31 · sector 18
HEALTH (low debt)34 · sector 95
DIVIDEND (yield)0 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Textile Manufacturing stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhou International Group 2313 HK$42.12 HK$72.40 +72% vs BIOKA
K.P.R. Mill Limited KPRMILL ₹1,164 ₹1,604 +38% vs BIOKA
Inner Mongolia ERDOS Resources Co 600295 ¥14.81 ¥16.12 +9% vs BIOKA
Far Eastern New Century Corporation 1402 27.25 TWD 27.89 TWD +2% vs BIOKA
Ruentex Industries Ltd 2915 53.10 TWD 48.61 TWD −8% vs BIOKA
Tongkun Group 601233 ¥23.37 ¥14.51 −38% vs BIOKA
Zhejiang Orient Holdings 600120 ¥4.34 ¥2.40 −45% vs BIOKA
Albany International Corp AIN $67.28 $24.93 −63% vs BIOKA
HMT (Xiamen) New Technical Materials Co 603306 ¥44.18 ¥14.96 −66% vs BIOKA
Welspun Living Limited WELSPUNLIV ₹241.30 ₹47.77 −80% vs BIOKA

Explore undervalued stocks

More undervalued Consumer Cyclical stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biokarpet S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Biokarpet S.A. Fair Value". https://www.fairvalue-calculator.com/stock/BIOKA

Frequently asked questions

Is Biokarpet S.A. (BIOKA) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of €2.58 versus a price of €1.47, about +76% upside (undervalued).
What is the fair value of BIOKA?
Our model-based fair value for Biokarpet S.A. is €2.58 (as of Nov 9, 2026), built from audited fundamentals. The current price: €1.47.
What is the quality score of BIOKA?
Biokarpet S.A. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biokarpet S.A. (BIOKA)?
Our model-based price target is the fair value of €2.58 (as of Nov 9, 2026) from 10 valuation models. Cautious scenario €1.81, optimistic scenario €3.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Biokarpet S.A. stock forecast for 2026?
Our models put fair value at €2.58, about +76% upside versus a price of €1.47 (undervalued). Cautious scenario €1.81, optimistic scenario €3.35. The calculation is refreshed regularly with new filings.
What is the revenue of Biokarpet S.A. (BIOKA)?
Biokarpet S.A. reported trailing-twelve-month revenue of about €228M (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Biokarpet S.A. (BIOKA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biokarpet S.A. it is €2.58 per share (as of Nov 9, 2026), against a price of €1.47. It is the blended result of 10 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Biokarpet S.A. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, BIOKA trades below its calculated fair value: price €1.47, fair value €2.58, a gap of about +76% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOKA?
No. The price is what the market pays today (€1.47); the fair value is what the company's own numbers justify (€2.58). For Biokarpet S.A. the two are €1.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biokarpet S.A. worth?
The market values Biokarpet S.A. at about €35.3M (market capitalisation, as of Nov 9, 2026). Per share that is €1.47; our models calculate a fair value of €2.58 per share.
What do the bullish and bearish scenarios say about BIOKA?
Our models span a range for Biokarpet S.A.: cautious scenario €1.81, base €2.58, optimistic €3.35 per share (as of Nov 9, 2026, price €1.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BIOKA?
Biokarpet S.A. trades at a price-to-earnings ratio of 163.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €2.58 is built from several models across several years.
How solid is the balance sheet of Biokarpet S.A. (BIOKA)?
Balance-sheet figures for Biokarpet S.A. (as of Nov 9, 2026): return on equity 7.7%, debt of 1.32 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is BIOKA from its 52-week high?
Biokarpet S.A. trades at €1.47, about 27% below its 52-week high of €2.00 and 2% above the low of €1.44 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €2.58 is for.
Which stocks are comparable to Biokarpet S.A.?
From the same area (Consumer Cyclical) we also value Tongkun Group, Shenzhou International Group, Inner Mongolia ERDOS Resources Co, Far Eastern New Century Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biokarpet S.A. stock attractive at the current price?
The data as of Nov 9, 2026: price €1.47, calculated fair value €2.58 (+76%), Quality Score 45/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOKA calculated?
We run Biokarpet S.A. through 10 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €2.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Biokarpet S.A. currently trades 43% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biokarpet S.A. (BIOKA)?
The closing price on Nov 6, 2026 was €1.47. Our model-based fair value is €2.58, about +76% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biokarpet S.A. right now?
The large discount to fair value meets weak quality (45/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (€1.81). The market is more pessimistic than our downside scenario. A fairly wide model range (€1.81 to €3.35) leaves room in how you read the outcome.

Key figures of Biokarpet S.A.

How large is the market capitalisation of Biokarpet S.A. (BIOKA)?
The market capitalisation of Biokarpet S.A. is €35.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Biokarpet S.A. (BIOKA)?
The price-to-sales ratio of Biokarpet S.A. is 0.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Biokarpet S.A. (BIOKA)?
Earnings per share at Biokarpet S.A. are €0.0090 (price ÷ EPS = P/E 163.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biokarpet S.A. (BIOKA)?
The net margin of Biokarpet S.A. is 1.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biokarpet S.A. (BIOKA)?
The return on equity (ROE) of Biokarpet S.A. is 7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biokarpet S.A. (BIOKA)?
On an EBIT basis the return on assets of Biokarpet S.A. is 5.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biokarpet S.A. (BIOKA)?
The operating margin of Biokarpet S.A. is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biokarpet S.A. (BIOKA)?
Revenue at Biokarpet S.A. is growing +13.1% versus a year earlier (3y avg −2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Biokarpet S.A. (BIOKA)?
Earnings per share at Biokarpet S.A. are growing +42.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Biokarpet S.A. (BIOKA) generate?
The free cash flow of Biokarpet S.A. is −€8.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Biokarpet S.A. (BIOKA) carry?
The net debt of Biokarpet S.A. is €114M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Biokarpet S.A. in the live analysis

One click puts Biokarpet S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.